Prevention of allergic reactions during oxaliplatin desensitization through inhibition of Bruton tyrosine kinase
- 21 March 2024
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 154 (1) , 222-228.e4
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- The Who, What, Where, When, Why, and How of Drug DesensitizationImmunology and Allergy Clinics of North America, 2022
- Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential FeaturesTargeted Oncology, 2021
- Hypersensitivity Reactions to Platinum Agents and TaxanesClinical Reviews in Allergy & Immunology, 2021
- Non–IgE-mediated anaphylaxisJournal of Allergy and Clinical Immunology, 2021
- World Allergy Organization Anaphylaxis Guidance 2020World Allergy Organization Journal, 2020
- Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergyJournal of Allergy and Clinical Immunology, 2018
- Platinum Chemotherapy HypersensitivityImmunology and Allergy Clinics of North America, 2017
- Oxaliplatin Hypersensitivity: Evaluation, Implications of Skin Testing, and DesensitizationThe Journal of Allergy and Clinical Immunology: In Practice, 2014
- Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitorInternational Immunopharmacology, 2011
- Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 casesJournal of Allergy and Clinical Immunology, 2008